Antitumor activity of CYT997: A phase II vascular disrupting agent administered orally in combination with cisplatin in a colon adenocarcinoma xenograft model

被引：1
|
作者：
Powell, Andrew K.
Shnyder, Steven D.
Cooper, Patricia A.
Nelson, Stuart
Burns, Christopher J.
Fida, Rose
Smith, Gregg D.
机构：
来源：
MOLECULAR CANCER THERAPEUTICS | 2009年 / 8卷 / 12期
关键词：
D O I：
10.1158/1535-7163.TARG-09-A16
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A16
引用
收藏
页数：3
相关论文
共 10 条
  • [1] Phase I evaluation of orally-administered CYT997, a novel cytotoxic vascular-disrupting agent, in patients with advanced cancer
    Francesconi, A.
    Kotasek, D.
    Burge, M.
    Smith, G.
    Lickliter, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [2] CYT997: Preclinical studies on the antivascular effects and mode of action of a phase II vascular disrupting agent
    Segal, David
    Gangatirkar, Pradnya
    Joffe, Max
    Shnyder, Steven
    Malcontenti-Wilson, Cathy
    Christophi, Chris
    Powell, Andrew
    Smith, Gregg
    Burns, Christopher
    Fantino, Emmanuelle
    CANCER RESEARCH, 2009, 69
  • [3] Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent
    J D Lickliter
    A B Francesconi
    G Smith
    M Burge
    A Coulthard
    S Rose
    M Griffin
    R Milne
    J McCarron
    T Yeadon
    A Wilks
    A Cubitt
    D K Wyld
    P A Vasey
    British Journal of Cancer, 2010, 103 : 597 - 606
  • [4] Phase I, pharmacokinetic and pharmacodynamic evaluation of CYT997, an orally-bioavailable cytotoxic and vascular-disrupting agent
    Burge, Matthew
    Francesconi, Alessandra B.
    Kotasek, Dusan
    Fida, Rosa
    Smith, Gregg
    Wilks, Andrew
    Vasey, Paul A.
    Lickliter, Jason D.
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (01) : 126 - 135
  • [5] Phase I, pharmacokinetic and pharmacodynamic evaluation of CYT997, an orally-bioavailable cytotoxic and vascular-disrupting agent
    Matthew Burge
    Alessandra B. Francesconi
    Dusan Kotasek
    Rosa Fida
    Gregg Smith
    Andrew Wilks
    Paul A. Vasey
    Jason D. Lickliter
    Investigational New Drugs, 2013, 31 : 126 - 135
  • [6] Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent
    Lickliter, J. D.
    Francesconi, A. B.
    Smith, G.
    Burge, M.
    Coulthard, A.
    Rose, S.
    Griffin, M.
    Milne, R.
    McCarron, J.
    Yeadon, T.
    Wilks, A.
    Cubitt, A.
    Wyld, D. K.
    Vasey, P. A.
    BRITISH JOURNAL OF CANCER, 2010, 103 (05) : 597 - 606
  • [7] CYT997: a novel orally active tubulin polymerization inhibitor with potent cytotoxic and vascular disrupting activity in vitro and in vivo
    Burns, Christopher J.
    Fantino, Emmanuelle
    Phillips, Ian D.
    Su, Stephen
    Harte, Michael F.
    Bukczynska, Patricia E.
    Frazzetto, Mark
    Joffe, Max
    Kruszelnicki, Irma
    Wang, Bing
    Wang, Yue
    Wilson, Neil
    Dilley, Rodney J.
    Wan, Soo S.
    Charman, Susan A.
    Shackleford, David M.
    Fida, Rosa
    Malcontenti-Wilson, Cathy
    Wilks, Andrew F.
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (11) : 3036 - 3045
  • [8] Phase I evaluation of CYT997, a novel cytotoxic and vascular-disrupting agent, in patients with advanced cancer
    Lickliter, J.
    Francesconi, A.
    Smith, G.
    Burge, M.
    Coulthard, A.
    Rose, S.
    Griffin, M.
    Wilks, A.
    Wyld, D.
    Vasey, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] Phase I study of CYT997, a novel cytotoxic and vascular disrupting agent, given as a 24-hour intravenous infusion to patients with advanced solid tumours
    Lickliter, J.
    Smith, G.
    Burge, M.
    Coulthard, A.
    Wyld, D.
    Wilks, A.
    Vasey, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [10] SAFETY AND ANTITUMOR ACTIVITY OF NGR-HTNF, A SELECTIVE VASCULAR TARGETING AGENT (VTA), ADMINISTERED AT LOW DOSE IN PRE-TREATED PATIENTS (PTS) WITH HEPATOCELLULAR CARCINOMA (HCC): PRELIMINARY RESULTS OF A PHASE II TRIAL
    Citterio, G.
    Santoro, A.
    Pressiani, T.
    Scalamogna, R.
    Gregorc, V.
    Rossoni, G.
    Donadoni, G.
    Caligaris-Cappio, F.
    Lambiase, A.
    Bordignon, C.
    ANNALS OF ONCOLOGY, 2008, 19 : 178 - 178
1